WO2012158591A1 - Anti-blepharitis products and methods - Google Patents

Anti-blepharitis products and methods Download PDF

Info

Publication number
WO2012158591A1
WO2012158591A1 PCT/US2012/037724 US2012037724W WO2012158591A1 WO 2012158591 A1 WO2012158591 A1 WO 2012158591A1 US 2012037724 W US2012037724 W US 2012037724W WO 2012158591 A1 WO2012158591 A1 WO 2012158591A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
phase
weight
blepharitis
shale oil
Prior art date
Application number
PCT/US2012/037724
Other languages
French (fr)
Inventor
Shetal A. SHAH
Monica DWECK
Ronald J. Bohm
Amit R. Shah
Original Assignee
The Research Foundation Of State University Of New York
Resources Of Nature, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation Of State University Of New York, Resources Of Nature, Inc. filed Critical The Research Foundation Of State University Of New York
Publication of WO2012158591A1 publication Critical patent/WO2012158591A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • A61Q1/10Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the disclosure relates generally to the field of products that can prevent or treat blepharitis. More specifically, the present disclosure is directed to preventing or treating blepharitis through application of various cosmetics.
  • Blepharitis is one of the most common ocular disorders, affecting millions of Americans. Blepharitis is a continuum of inflammatory disease processes of the eyelid and can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis is inflammation around the eyelashes and follicles, while posterior type involves the meibomian glands. The
  • pathophysiology of blepharitis involves bacterial colonization of the eyelids. This bacterial colonization results in immune mediated inflammatory damage to the surrounding tissues.
  • formulations of cosmetics that can be used to treat or prevent blepharitis. Further, what is desired are formulations that have anti-bacterial and antiinflammatory effects that can be used as cosmetics.
  • Embodiments of the present application provide products and methods that address the above and other issues.
  • the present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis.
  • the process is directed towards a cosmetic composition comprising verbascoside and a shale oil.
  • the present disclosure is also directed to a method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
  • the present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
  • compositions of the present disclosure provide improvements over traditional cosmetics that cause or exacerbate blepharitis symptoms.
  • the improvements are, inter alia, treatment or prevention of blepharitis symptoms and blepharitis through application of the described cosmetic compositions.
  • Various cosmetic compositions are disclosed herein.
  • Each cosmetic composition includes both 2-(3',4'-dihydroxyphenyl)ethyl-0-a-l-rhamnopyranosyl-(l ⁇ 3)- -d-(4-0- caffeoyl)-glucopyranoside (Verbascoside), also known as kusaginin or acetoside, and a shale oil, among other components.
  • These other components can include one or more cosmetically suitable excipients such as glycerine and xantham gum.
  • These other components comprise the balance of the total composition as further illustrated among the several examples below, with their individual concentrations depending on the kind of cosmetic composition being produced. Individual concentrations of the suitable excipients are listed in the examples, but these individual concentrations may be modified in either direction, higher or lower percentage, as needed.
  • the shale oil can be any shale oil suitable for topical use including light-colored pale sulfonated shale oil (ICHTHYOL® pale) and dark sulfonated shale oil (ICHTHYOL®).
  • the shale oil can be present in concentrations ranging from 0.0001% by weight to about 10% by weight of the total composition.
  • the shale oil is useful as an anti-inflammatory, anti -bacterial and antimycotic when applied topically and is also water soluble.
  • the other components can include a metal ion carrier that can contain any suitable metal ion that is capable of offering and anti-inflammatory or anti-bacterial effect.
  • the inorganic metal ion carrier can be an inorganic silver ion carrier.
  • the inorganic silver ion carrier can be Ionpure® WP A glass powder, among others.
  • Ionpure® is an inorganic, soluble glass containing anti-bacterial metal ions.
  • the Ionpure® glass particles are non- volatile, heat resistant and in the presence of water or moisture, will release the metal ions gradually.
  • Metal ions, such as silver ions, are taken into microbes where they react, bond and inhibit the microbe's enzyme activity and can reduce multiplication of the microbes. These microbes can include blepharitis causing bacteria.
  • the other components can also include glycerophosphoinositol (GPI) lysine.
  • GPI Lysine such as Distinctive® GPI Lysine offered by Resources of Nature, Inc. South Plainfield, New Jersey, is useful as an anti-inflammatory and anti-itch substance.
  • GPI lysine is stable over a broad range of temperatures and pH's and can be present in concentrations ranging from
  • Verbascoside is an effective cellular protectant that can be applied topically.
  • Verbascoside can be isolated or extracted from various raw materials.
  • verbascoside can be gathered from the leaves of the buddleja cordata tree. The leaves can be dried, ground and extracted with hexane and methanol. The methanolic portion is evaporated to obtain a crude syrup that is further treated to produce a verbascoside amorphous powder.
  • Verbascoside is a phenylpropanoid glycoside (PPG) that is a water soluble derivative of phenylpropanoid (PP).
  • PPG phenylpropanoid glycoside
  • PP phenylpropanoid
  • Verbascoside has a strong anti-inflammatory and anti-bacterial activity.
  • Distinctive® Phytostem Lilac is one example of a material containing verbascoside, but any other suitable verbascoside containing material could also be used.
  • Distinctive® Phytostem Lilac is a cell culture extract titrated in verbascoside.
  • the verbascoside and shale oil can be encapsulated, the shale oil and the GPI lysine can also be encapsulated.
  • the encapsulated materials can be immediate, sustained or a mixture of immediate and sustained release encapsulations.
  • the materials can be encapsulated in any suitable manner, such as the encapsulation methods described in European Patent EP0966268 and those described in "Drug Delivery: Principles and Applications" by Wang, et al. (John Wiley & Sons, Inc. 2005), both of which are incorporated by reference.
  • the verbascoside and the inorganic metal ion carrier can be differing concentrations based on the desired result.
  • the verbascoside can be about 0.0001% by weight to about 10% by weight of the composition and the inorganic metal ion carrier can be about 0.0001% by weight to about 10% by weight.
  • the cosmetic composition can be one of many cosmetic compositions, which can include lotions, creams, eye pencils, eye shadows, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray. These cosmetic compositions can be applied topically on any exposed skin surface that could be affected by blepharitis including, but not limited to, eye lids and the areas surrounding each of the eyes. These cosmetic compositions can be formed using various manufacturing techniques, some of which are described throughout the examples below. Blepharitis can have many different causes, including but not limited to Staphococyl, Seborrheaic, Allergies, Lice, cosmetic products and others from other sources other than cosmetic products.
  • the disclosure also includes a method for preventing or treating blepharitis that includes administering a therapeutic amount of verbascoside and shale oil.
  • the administration of the verbascoside and shale oil is useful in both preventing the presence of blepharitis and blepharitis symptoms, it is also useful in treating the severity of the blepharitis and blepharitis symptoms such as the reduction of sebum production, reduction of bacterial growth and the unclogging of skin's pores.
  • the combination of verbascoside and shale oil provides improved blepharitis prevention and treatment as compared to the administration of verbascoside alone or shale oil alone.
  • the combination can be synergistic, e.g., where the joint action of two or more components is such that the combined effect is greater than the sum of their individual effects.
  • ICHTHYOL® pale is included.
  • lonpure® WPA glass powder can also be used, instead of or in combination with ICHTHYOL® pale, in similar percentages by weight.
  • composition is an oil in water lotion:
  • the oil in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D and E ingredients are then added.
  • composition is an oil in water cream:
  • the oil in water cream is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase D, E and F ingredients are then added.
  • composition is water in oil lotion:
  • Salicylic Acid (as 0.1% to applicable) 20%
  • the water in oil lotion is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is water in oil cream:
  • the water in oil cream is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is for an eye pencil "A":
  • the eye pencil "A” is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye.
  • composition is for an eye pencil "B":
  • the eye pencil "B" is formed by combining all components of Phase A and heating the mixture to 95 °C. After heating, the mixture is mixed until uniform and cooled to room temperature. The mixture is then formed into a suitable shape for application to a user's eye.
  • composition is for an eye shadow:
  • composition is for a silicon in water lotion:
  • the silicon in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerin and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is for a water in silicone lotion:
  • the water in silicone lotion is formed by first preparing phase A by adding Butylene glycol, glycerin, sodium chloride and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is for a hydroalcoholic liquid or spray:
  • the hydroalcoholic liquid or spray is formed by first preparing phase A by combining all Phase A components. Next, the Phase B, C, D and E components are mixed together and combined with the Phase A components. [0043] In the following example, the composition is for a cosmetic primer:
  • Cosmetic primer is formed by first preparing phase A by combining all Phase A components. Next, the Phase E, F and G components are mixed together and combined with the Phase A components. owing example, the composition is for a cosmetic serum:
  • the cosmetic serum is formed by first preparing phase A by adding Butylene glycol, glycerin, glyceryl acrylate/acrylic acid copolymer and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
  • composition is for a mascara:
  • Camauba Wax (Copernicia Cerifera (Carnauba) Wax) 5.00
  • Salicylic Acid 0.1% to 20%
  • Phase C Retinol or Retinol derivatives 0.01% to 0.25%
  • Distinctive® Phytostem Lilac 50 (Maltodextrin (and) Syringa Vulgaris
  • Colorants qs [0048] All percentages above are based on weight.
  • the cosmetic serum is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
  • composition is for a waterproof mascara:
  • Waterproof mascara is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye. [0051] In the following example, the composition is for an eyeliner containing iron oxide
  • Eyeliner containing iron oxide is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
  • composition is for an eyeliner:
  • Eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
  • Example 17
  • composition is for an anhydrous eyeliner:
  • Anhydrous eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
  • composition is for a mascara containing iron oxide:
  • the mascara containing iron oxide is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
  • composition is for a single phase cosmetic liquid or spray:
  • a single phase cosmetic liquid or spray is formed by first preparing phase A by combining all Phase A components. The components are mixed until uniform, and added to the Phase B, C, D and E components.
  • composition is for a wet wipe cloth and liquid:

Abstract

The present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis. The process is directed towards a cosmetic composition including verbascoside and a shale oil. The present disclosure is also directed to a method for preventing blepharitis including administering a therapeutic amount of verbascoside and a shale oil. The present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.

Description

ANTI-BLEPHARITIS PRODUCTS AND METHODS
FIELD OF THE DISCLOSURE
[0001] The disclosure relates generally to the field of products that can prevent or treat blepharitis. More specifically, the present disclosure is directed to preventing or treating blepharitis through application of various cosmetics.
BACKGROUND OF THE DISCLOSURE
[0002] Blepharitis is one of the most common ocular disorders, affecting millions of Americans. Blepharitis is a continuum of inflammatory disease processes of the eyelid and can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis is inflammation around the eyelashes and follicles, while posterior type involves the meibomian glands. The
pathophysiology of blepharitis involves bacterial colonization of the eyelids. This bacterial colonization results in immune mediated inflammatory damage to the surrounding tissues.
[0003] People with blepharitis typically present with various complaints including burning, watery eyes, foreign body sensation, red eye lids, red eyes, pain and blurry vision. Physical examination of patients with blepharitis often shows loss of lashes, plugging of the meibomian glands and injection of the conjunctiva. Also, the irritation that blepharitis causes can often lead to dry eyes. If the blepharitis is severe enough it may even affect the cornea, causing marginal infiltrates, marginal ulcers and pannus formation.
[0004] Ophthalmologists often see female patients wearing heavy cosmetics, complaining of symptoms of blepharitis. In these situations, even though the patients are advised to stop wearing the cosmetics, patients typically refuse to stop wearing cosmetics because they like how the cosmetics make them appear.
[0005] What is desired are formulations of cosmetics that can be used to treat or prevent blepharitis. Further, what is desired are formulations that have anti-bacterial and antiinflammatory effects that can be used as cosmetics.
[0006] Embodiments of the present application provide products and methods that address the above and other issues.
SUMMARY OF THE DISCLOSURE
[0007] The present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis. The process is directed towards a cosmetic composition comprising verbascoside and a shale oil.
[0008] The present disclosure is also directed to a method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
[0009] The present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0010] The methods and compositions of the present disclosure provide improvements over traditional cosmetics that cause or exacerbate blepharitis symptoms. The improvements are, inter alia, treatment or prevention of blepharitis symptoms and blepharitis through application of the described cosmetic compositions. [0011] Various cosmetic compositions are disclosed herein. Each cosmetic composition includes both 2-(3',4'-dihydroxyphenyl)ethyl-0-a-l-rhamnopyranosyl-(l→3)- -d-(4-0- caffeoyl)-glucopyranoside (Verbascoside), also known as kusaginin or acetoside, and a shale oil, among other components. These other components can include one or more cosmetically suitable excipients such as glycerine and xantham gum. These other components comprise the balance of the total composition as further illustrated among the several examples below, with their individual concentrations depending on the kind of cosmetic composition being produced. Individual concentrations of the suitable excipients are listed in the examples, but these individual concentrations may be modified in either direction, higher or lower percentage, as needed.
[0012] The shale oil can be any shale oil suitable for topical use including light-colored pale sulfonated shale oil (ICHTHYOL® pale) and dark sulfonated shale oil (ICHTHYOL®). The shale oil can be present in concentrations ranging from 0.0001% by weight to about 10% by weight of the total composition. The shale oil is useful as an anti-inflammatory, anti -bacterial and antimycotic when applied topically and is also water soluble. The other components can include a metal ion carrier that can contain any suitable metal ion that is capable of offering and anti-inflammatory or anti-bacterial effect. As one option, the inorganic metal ion carrier can be an inorganic silver ion carrier. The inorganic silver ion carrier can be Ionpure® WP A glass powder, among others. Ionpure® is an inorganic, soluble glass containing anti-bacterial metal ions. The Ionpure® glass particles are non- volatile, heat resistant and in the presence of water or moisture, will release the metal ions gradually. Metal ions, such as silver ions, are taken into microbes where they react, bond and inhibit the microbe's enzyme activity and can reduce multiplication of the microbes. These microbes can include blepharitis causing bacteria.
[0013] The other components can also include glycerophosphoinositol (GPI) lysine. GPI Lysine, such as Distinctive® GPI Lysine offered by Resources of Nature, Inc. South Plainfield, New Jersey, is useful as an anti-inflammatory and anti-itch substance. GPI lysine is stable over a broad range of temperatures and pH's and can be present in concentrations ranging from
0.0001% by weight to about 10% by weight of the total composition.
[0014] Verbascoside is an effective cellular protectant that can be applied topically.
Verbascoside can be isolated or extracted from various raw materials. In one example, verbascoside can be gathered from the leaves of the buddleja cordata tree. The leaves can be dried, ground and extracted with hexane and methanol. The methanolic portion is evaporated to obtain a crude syrup that is further treated to produce a verbascoside amorphous powder.
[0015] Verbascoside is a phenylpropanoid glycoside (PPG) that is a water soluble derivative of phenylpropanoid (PP). Verbascoside has a strong anti-inflammatory and anti-bacterial activity. Distinctive® Phytostem Lilac is one example of a material containing verbascoside, but any other suitable verbascoside containing material could also be used. Distinctive® Phytostem Lilac is a cell culture extract titrated in verbascoside.
[0016] The verbascoside and shale oil can be encapsulated, the shale oil and the GPI lysine can also be encapsulated. The encapsulated materials can be immediate, sustained or a mixture of immediate and sustained release encapsulations. The materials can be encapsulated in any suitable manner, such as the encapsulation methods described in European Patent EP0966268 and those described in "Drug Delivery: Principles and Applications" by Wang, et al. (John Wiley & Sons, Inc. 2005), both of which are incorporated by reference.
[0017] In the cosmetic composition, the verbascoside and the inorganic metal ion carrier can be differing concentrations based on the desired result. In the cosmetic composition, the verbascoside can be about 0.0001% by weight to about 10% by weight of the composition and the inorganic metal ion carrier can be about 0.0001% by weight to about 10% by weight.
[0018] The cosmetic composition can be one of many cosmetic compositions, which can include lotions, creams, eye pencils, eye shadows, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray. These cosmetic compositions can be applied topically on any exposed skin surface that could be affected by blepharitis including, but not limited to, eye lids and the areas surrounding each of the eyes. These cosmetic compositions can be formed using various manufacturing techniques, some of which are described throughout the examples below. Blepharitis can have many different causes, including but not limited to Staphococyl, Seborrheaic, Allergies, Lice, cosmetic products and others from other sources other than cosmetic products.
[0019] The disclosure also includes a method for preventing or treating blepharitis that includes administering a therapeutic amount of verbascoside and shale oil. The administration of the verbascoside and shale oil is useful in both preventing the presence of blepharitis and blepharitis symptoms, it is also useful in treating the severity of the blepharitis and blepharitis symptoms such as the reduction of sebum production, reduction of bacterial growth and the unclogging of skin's pores. [0020] Surprisingly, the combination of verbascoside and shale oil provides improved blepharitis prevention and treatment as compared to the administration of verbascoside alone or shale oil alone. The combination can be synergistic, e.g., where the joint action of two or more components is such that the combined effect is greater than the sum of their individual effects.
[0021] The following examples serve to illustrate aspects of the disclosure but are not intended to limit the scope of the disclosure, which is defined by the claims appended hereto.
EXAMPLES
[0022] For each of the examples below, ICHTHYOL® pale is included. For each of the examples, lonpure® WPA glass powder can also be used, instead of or in combination with ICHTHYOL® pale, in similar percentages by weight.
Example 1
[0023] In the following example, the composition is an oil in water lotion:
Figure imgf000008_0001
Phase
E Preservative qs
[0024] All percentages above are based on weight. The oil in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D and E ingredients are then added.
example, the composition is an oil in water cream:
Figure imgf000010_0001
[0026] All percentages above are based on weight. The oil in water cream is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase D, E and F ingredients are then added.
Example 3
[0027] In the following example, the composition is water in oil lotion:
Ingredient %(w/w)
Phase
A Deionized Water qs
1,3 Butylene Glycol 5.00
Glycerine 3.00
Disodium EDTA 0.10
Sodium Chloride 2.00
Sodium Borate 0.15
Glycolic Acid or Lactic 2% to
Acid 10%
(as applicable)
Phase
B Mineral Oil 70 vis. 10.00
Petrolatum 4.00
Cetyl Alcohol 2.00
Behenyl Alcohol 1.00
Beeswax 2.50
Dimethicone (350 cks) 1.00
PEG 100 Stearate 3.00
Salicylic Acid (as 0.1% to applicable) 20%
Sorbitan Sesquioleate 0.80
Tocopheryl Acetate 0.50
Phase Distinctive® Phytostem
C Lilac 50 (Maltodextrin
(and) Syringa Vulgaris
(Lilac) Leaf Cell Culture
Extract 0.50
Sodium Sulfonated Shale
Oil 1.00
Retinol or Retinol 0.01% to derivatives 0.25%
(as applicable)
Phase
D Fragrance qs
Phase
E Preservative qs
Phase
F Colorants qs [0028] All percentages above are based on weight. The water in oil lotion is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 4
[0029] In the following example, the composition is water in oil cream:
Figure imgf000014_0001
[0030] All percentages above are based on weight. The water in oil cream is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 5
[0031] In the following example, the composition is for an eye pencil "A":
Figure imgf000016_0001
[0032] All percentages above are based on weight. The eye pencil "A" is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye.
Example 6
[0033] In the following example, the composition is for an eye pencil "B":
Figure imgf000018_0001
[0034] All percentages above are based on weight. The eye pencil "B" is formed by combining all components of Phase A and heating the mixture to 95 °C. After heating, the mixture is mixed until uniform and cooled to room temperature. The mixture is then formed into a suitable shape for application to a user's eye.
[0035] In the following example, the composition is for an eye shadow:
Figure imgf000020_0001
[0036] All percentages above are based on weight. The eye shadow is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye. Example 8
[0037] In the following example, the composition is for a silicon in water lotion:
Figure imgf000021_0001
[0038] All percentages above are based on weight. The silicon in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerin and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 9
[0039] In the following example, the composition is for a water in silicone lotion:
Ingredient %(w/w)
Phase
A Deionized Water Qs
1,3 Butylene Glycol 5.00
Glycerin 3.00
Glycolic Acid or Lactic Acid 2% to
(as applicable) 10%
Disodium EDTA 0.10
Sodium Chloride 2.00
Phase
B Cyclopentasiloxane 25.00
Polysilicone-11 6.00
Cetyldimethicone Copolyol 1.50
Phenyl Dimethicone 5.00
Ethylhexyl Palmitate 5.00
0.1% to
Salicylic Acid (as applicable) 20%
Phenyl Dimethicone 20.00
Tocopheryl Acetate 0.50
Cetyl Alcohol 2.00
Behenyl Alcohol 1.00
Dimethicone (350 cks) 3.00
Sorbitan Sesquioleate 0.80
Phase
C Distinctive® Phytostem Lilac 50
(Maltodextrin (and) Syringa Vulgaris
(Lilac) Leaf Cell Culture Extract 0.50
Sodium Sulfonated Shale Oil 1.00
Retinol or Retinol derivatives 0.01%
(as applicable) to
0.25%
Phase
D Fragrance Qs
Phase
E Preservative Qs
Phase
F Colorants Qs [0040] All percentages above are based on weight. The water in silicone lotion is formed by first preparing phase A by adding Butylene glycol, glycerin, sodium chloride and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 10
[0041] In the following example, the composition is for a hydroalcoholic liquid or spray:
Figure imgf000025_0001
[0042] All percentages above are based on weight. The hydroalcoholic liquid or spray is formed by first preparing phase A by combining all Phase A components. Next, the Phase B, C, D and E components are mixed together and combined with the Phase A components. [0043] In the following example, the composition is for a cosmetic primer:
Figure imgf000026_0001
[0044] All percentages above are based on weight. Cosmetic primer is formed by first preparing phase A by combining all Phase A components. Next, the Phase E, F and G components are mixed together and combined with the Phase A components. owing example, the composition is for a cosmetic serum:
Ingredient %(w/w)
Phase
A Deionized Water qs
1,3 Butylene Glycol 5.00
Glyceryl Acrylate/Acrylic Acid Copolymer 5.00
Glycerin 5.00
Disodium EDTA 0.10
Allantoin 0.25
Xanthan Gum 0.30
Glycolic Acid or Lactic Acid 2% to
(as applicable) 10%
Phase
B Ethylhexyl Palmitate 10.00
Isononyl Isononanoate 4.00
Cetyl Alcohol 1.00
Behenyl Alcohol 1.00
Dimethicone (350 cks) 1.00
Phospholipids 3.00
Hydrogenated Lecithin 2.00
Laureth 4 1.00
0.1% to
Salicylic Acid (as applicable) 20%
PEG 100 Stearate 3.00
Polysorbate 20 0.80
Phase Retinol or Retinol derivatives 0.01%
C (as applicable) to
0.25%
Vitamin E Acetate 1.00
Phase Distinctive® Phytostem Lilac 50 (Maltodextrin
D (and) Syringa Vulgaris (Lilac) Leaf Cell Culture
Extract 0.50
Sodium Sulfonated Shale Oil 1.00
Phase
E Fragrance qs
Phase
F Preservative qs
Phase
G Colorants qs [0046] All percentages above are based on weight. The cosmetic serum is formed by first preparing phase A by adding Butylene glycol, glycerin, glyceryl acrylate/acrylic acid copolymer and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
Example 13
[0047] In the following example, the composition is for a mascara:
Ingredient %(w/ )
Phase A Deionized Water qs
Hydroxyethylcellulose 0.75
Distinctive Ink Black Chip AQ (D&C Black #2 (and) Polyester-5 (and)
PVP (and) Laureth-4) 6.00
DC Instalift Lengthening (Water (and) PVP (and) Triticum vulgare
(Wheat) Protein (and) Gossypium Herbaceum (Cotton)) 5.00
DC Hydroglide (Glycerin (and) Water (and) Glycine Soja (Soybean)
Germ Extract (and) Beta Vulgaris (Beet) Root Extract (and) Algae
Extract (and) Sodium Hyaluronate 3.00
Tromethamine 40% 5.69
Preservative q.s.
Glycolic Acid or Lactic Acid 2% to 10% (as applicable)
Phase B Glyceryl Stearate 4.00
Camauba Wax (Copernicia Cerifera (Carnauba) Wax) 5.00
Stearic Acid 4.00
Propylene Glycol Stearate 2.00
Beeswax 4.00
CI 8-36 Triglyceride 0.40
Paraffin Wax (Paraffin) 1.00
Salicylic Acid (as applicable) 0.1% to 20%
Phase C Retinol or Retinol derivatives 0.01% to 0.25%
(as applicable)
Phase D Acrylates Copolymer 10.00
Phase E DC Silica Beads (Silica) 2.00
Distinctive® Phytostem Lilac 50 (Maltodextrin (and) Syringa Vulgaris
(Lilac) Leaf Cell Culture Extract 0.50
DI Water 4.00
Phase F Sodium Sulfonated Shale Oil 1.00
Phase G Fragrance qs
Colorants qs [0048] All percentages above are based on weight. The cosmetic serum is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
Example 14
[0049] In the following example, the composition is for a waterproof mascara:
Figure imgf000031_0001
[0050] All percentages above are based on weight. Waterproof mascara is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye. [0051] In the following example, the composition is for an eyeliner containing iron oxide
Figure imgf000032_0001
[0052] All percentages above are based on weight. Eyeliner containing iron oxide is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye. Example 16
[0053] In the following example, the composition is for an eyeliner:
Figure imgf000033_0001
[0054] All percentages above are based on weight. Eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye. Example 17
[0055] In the following example, the composition is for an anhydrous eyeliner:
Figure imgf000034_0001
[0056] All percentages above are based on weight. Anhydrous eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
Example 18
[0057] In the following example, the composition is for a mascara containing iron oxide:
Figure imgf000036_0001
[0058] All percentages above are based on weight. The mascara containing iron oxide is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
Example 19
[0059] In the following example, the composition is for a single phase cosmetic liquid or spray:
Figure imgf000038_0001
[0060] All percentages above are based on weight. A single phase cosmetic liquid or spray is formed by first preparing phase A by combining all Phase A components. The components are mixed until uniform, and added to the Phase B, C, D and E components.
Example 20
[0061] In the following example, the composition is for a wet wipe cloth and liquid:
Figure imgf000039_0001
[0062] All percentages above are based on weight. The wet wipe and liquid are formed by combining phase A ingredients and mixing until uniform. Phase B ingredients are then added and mixed until uniform.

Claims

CLAIMS What is claimed is:
1. A cosmetic composition comprising verbascoside and a shale oil.
2. The composition of claim 1, further comprising one or more cosmetically suitable excipients.
3. The composition of claim 1, wherein the shale oil is ICHTHYOL® pale.
4. The composition of claim 1, further comprising an inorganic metal ion carrier.
5. The composition of claim 4, wherein the inorganic metal ion carrier is an inorganic silver ion carrier.
6. The composition of claim 5, wherein the inorganic silver ion carrier is a glass containing silver ions.
7. The composition of claim 6, wherein the glass containing silver ions is silver borosilicate.
8. The composition of claim 1, wherein the composition comprises a lotion, cream, eye pencil, eye shadow, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray.
9. The composition of claim 1, wherein the verbascoside comprises from about 0.0001% by weight to about 10% by weight of the composition and shale oil comprises from about 0.0001% by weight to about 10% by weight.
10. The composition of claim 1, wherein the shale oil comprises from about 0.0001% by weight to about 10% by weight of the composition.
11. The composition of claim 1, further comprising glycerophosphomositol (GPI) lysine.
12. The composition of claim 10, wherein the GPI lysine comprises from about 0.0001% by weight to about 10% by weight of the composition.
13. A method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
14. A method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
PCT/US2012/037724 2011-05-18 2012-05-14 Anti-blepharitis products and methods WO2012158591A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487430P 2011-05-18 2011-05-18
US61/487,430 2011-05-18

Publications (1)

Publication Number Publication Date
WO2012158591A1 true WO2012158591A1 (en) 2012-11-22

Family

ID=47177293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037724 WO2012158591A1 (en) 2011-05-18 2012-05-14 Anti-blepharitis products and methods

Country Status (1)

Country Link
WO (1) WO2012158591A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130763A1 (en) * 2013-05-09 2014-11-10 Altergon Sa MONODOSE AND MULTIDOSE TOPIC PREPARATIONS FOR THE TREATMENT OF INFLAMMATORY STATES OF MUCOSE AND SKIN
WO2016000663A1 (en) * 2014-07-03 2016-01-07 杏辉天力(杭州)药业有限公司 Use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells
US9642887B1 (en) * 2015-12-28 2017-05-09 Shetal Amit Shah Anti-blepharitis compositions and their use
IT202100028220A1 (en) * 2021-11-05 2023-05-05 Novax Pharma Sam Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102289A1 (en) * 2000-11-30 2002-08-01 Anja Drucks Cosmetic or dermatological impregnated wipes
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7625883B1 (en) * 2000-11-07 2009-12-01 I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
US20100086502A1 (en) * 2008-10-08 2010-04-08 L'oreal Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor
US7718199B2 (en) * 2005-06-20 2010-05-18 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625883B1 (en) * 2000-11-07 2009-12-01 I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
US20020102289A1 (en) * 2000-11-30 2002-08-01 Anja Drucks Cosmetic or dermatological impregnated wipes
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7718199B2 (en) * 2005-06-20 2010-05-18 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use
US20100086502A1 (en) * 2008-10-08 2010-04-08 L'oreal Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130763A1 (en) * 2013-05-09 2014-11-10 Altergon Sa MONODOSE AND MULTIDOSE TOPIC PREPARATIONS FOR THE TREATMENT OF INFLAMMATORY STATES OF MUCOSE AND SKIN
WO2014180565A1 (en) * 2013-05-09 2014-11-13 Altergon S.A. Topical preparations comprising hyaluronic acid, verbascoside and glycerophosphoinositol
US20160113960A1 (en) * 2013-05-09 2016-04-28 Altergon S.A. Topical preparations comprising hyaluronic acid, verbascoside and glycerophosphoinositol
WO2016000663A1 (en) * 2014-07-03 2016-01-07 杏辉天力(杭州)药业有限公司 Use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells
US10967029B2 (en) 2014-07-03 2021-04-06 Sinphar Pharmaceutical Co., Ltd. Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress
US9642887B1 (en) * 2015-12-28 2017-05-09 Shetal Amit Shah Anti-blepharitis compositions and their use
EP3187186A1 (en) * 2015-12-28 2017-07-05 Shetal Amit Shah Anti-blepharitis compositions and their use
IT202100028220A1 (en) * 2021-11-05 2023-05-05 Novax Pharma Sam Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject
WO2023079520A1 (en) 2021-11-05 2023-05-11 Novax Pharma Sam Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject

Similar Documents

Publication Publication Date Title
TWI353861B (en)
US20060165644A1 (en) Cosmetics
CN109431873B (en) Composition for repairing and relieving skin inflammation
KR101425031B1 (en) Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil
US20140106009A1 (en) Methods and compositions for maintaining and improving the health of skin
TW201940187A (en) Topical skin care compositions
WO2012158591A1 (en) Anti-blepharitis products and methods
US9642887B1 (en) Anti-blepharitis compositions and their use
JP3556595B2 (en) Cosmetic composition for skin protection containing retinol and epidermal growth factor
KR20200073970A (en) Soothing cream and manufacturing method for the same
KR102300581B1 (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
KR102214985B1 (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
EP2983684B1 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
CN103494737A (en) Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation
KR20170092281A (en) Cosmetic Composition for Improving Acnes Using Chamomile
WO2014094377A1 (en) Bee venom composition with effects of protecting and beautifying lip
KR101418366B1 (en) Composition containing bee venom and propolis for preventing or treating acne
KR20070011939A (en) Cosmetic material including extract of camellia flower for skin abirritation
EP3378475B1 (en) Composition and kit for the use in the prevention of recurrent onychomycosis
WO2016033899A1 (en) Dandruff removing composition for adjusting scalp oil balance
CN107875079B (en) Fat-particle-removing essence and preparation method thereof
KR20040056079A (en) Cosmetic composition for preventing and therapeutic for a pimple
KR101773390B1 (en) Cosmetic composition for improving acne
KR102410642B1 (en) Hypoallergenic composition for perming eyelashes
KR102113866B1 (en) Cosmetic composition comprising extract of centella asiatica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12786016

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12786016

Country of ref document: EP

Kind code of ref document: A1